Diosynth


Diosynth, or Fujifilm Diosynth Biotechnologies, is a company that develops and offers manufacturing processes for active ingredients for pharmaceutical companies all over the world.

History

The company started in Oss, Netherlands in 1923 with the extraction of insulin from bovine pancreas, and porcine insulin extraction in 1930, both of which are still part of their main products. In January 2005, the company became a part of Organon, one of its sister companies in the Akzo Nobel pharma group. Along with its sister companies Organon and Intervet were sold to Schering-Plough in March 2007 by Akzo Nobel. Following the mergers of Schering-Plough with Merck & Co. on March 9, 2009, the company was part of the MSD Nutritionals products company, belonging to the MSD group. In April 2011, the company was sold to Fujifilm and Fujifilm Diosynth Biotechnologies was formed. On December 18, 2014, Fujifilm Diosynth Biotechnologies acquired Kalon Biotherapeutic Technologies in College Station, TX, which became Fujifilm Diosynth Biotechnologies Texas, LLC.
In March 2020, Fujifilm Diosynth Biotechnologies named Martin Meeson the company's new CEO. He will be taking over from Steve Bagshaw who is set to retire and become a non-executive chairman.